EP1267864A1 - A synergistic anti-malarial formulation - Google Patents

A synergistic anti-malarial formulation

Info

Publication number
EP1267864A1
EP1267864A1 EP00940733A EP00940733A EP1267864A1 EP 1267864 A1 EP1267864 A1 EP 1267864A1 EP 00940733 A EP00940733 A EP 00940733A EP 00940733 A EP00940733 A EP 00940733A EP 1267864 A1 EP1267864 A1 EP 1267864A1
Authority
EP
European Patent Office
Prior art keywords
formulation
rectal
arteether
treatment
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00940733A
Other languages
German (de)
French (fr)
Inventor
Guru Prakash Central Institute DUTTA
Dharm Chand Central Institute JAIN
Rajendra Singh Central Institute BHAKUNI
Sudhanshu Central Institute SAXENA
Sangeeta Central Institute DHAWAN
Suman Preeet Singh Central Institute KHANUJA
Sushil Central Institute KUMAR
Renu Central Drug Research Institute TRIPATHI
Aseem Central Drug Research Institute UMESH
Nuzhat Central Drug Research Institute KAMAL
Anil Kumar Central Drug Research Inst. DWIVEDI
Satyawan Central Drug Research Institute SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP1267864A1 publication Critical patent/EP1267864A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel synergistic formulation comprising ⁇ , ⁇ -arteether together with vegetable oil, said formulation useful in the treatment of comatose and cerebral malarial cases.
  • the formulation specifically useful for rectal route treatment of highly multi-drug resistant P. falciparum and P. vivax cases and which can be used for emergency treatment of comatose and cerebral malaria.
  • the invention also provides methods of treatment of malaria affecting the brain employing the novel formulation.
  • the invention also provides process for preparation of the said novel formulation.
  • Mefloquine was reported to produce neuropsychiatric side-effects in adults who developed tonic clonic fits. Besides psychosis, delusions and hallucinations, anxiety sleep disturbances were also reported after mefloquine (Drugs 1990, 39, 160-169).
  • Multi-drug-resistance in P. falciparum malaria and high level of P. vivax resistant strains are posing a major threat to countries in South-east Asia. Africa and Southern America. Most seriously affected areas include Thai-Myanmar Burmese border, where resistance to nearly all available drugs (Chlorquine, sulfadoxine-pyrimethamine, mefloquine, quinine) has already got established, (WHO Report on Infectious Diseases, 1999, WHO/CDS/99 1)
  • Halofant ⁇ ne ts more effective but rather high doses of the drug are now required to control resistant P. falciparum (Brasseur et al 1993 Lancet 341, 901-2) which cold lead to increased risk of cardiotoxicity of this new antimalarial including sinus bradycardia, sinus arrhythmia, tall peak T waves, QT interval prolongation, ectopic beats (Karbwang et al 1993, Lancet, 342, 501, Wildling et al 1993 Lancet, 342, 55, Kremsner et al Am J Trop Med Hyg 50, 790-795) which has imposed great limitation on the antimalarial potential of this drug Several reports have recently appeared which document emergence of chloroquine resistance by P.
  • ⁇ , ⁇ -arteether is an ethylether derivative of qinghaosu (artemisinine), which is extracted from Artemisia anniia, a plant long known in traditional Chinese medicine for its antimalarial properties
  • ⁇ , ⁇ -Arteether (30 70) is one of the artemisinin derivatives that has been developed in India and shows antimalarial activity against chloroquine, mefloquine and quinine resistant P. yoeln mgenensis and cures experimental cerebral malaria infections P. knowlesilP.
  • ⁇ / ⁇ -Arteether is relatively safer and its LD 50 dose is 1250 mg/kg in Swiss mice as compared to artemether (LD 50 263 mg/kg (im) and artesunate (LD50 475 mg/kg, im)(J Trad Chinese Med 1982,2(1) 31-38).
  • Clinical trials of intramuscular injection of this compound have been completed and marketed Data on clinical trials with injectible preparation of ⁇ , ⁇ arteether (30 70 mixtures of isomers amongst P. falciparum cases has been published (Mohapatra et al 1996 Indian J Med Res 104, 284-7, Nalecha et al 1997, Int J Clin Pharm Res XNII (1) 11-15 Mohanty et al 1997 Trans. R Soc Trop Med Hyg 91, 328-330, Mishra et / 1995, Trans R Soc. Trop Med Hyg 89, 299-301)
  • the main objective of the present invention is to provide a useful synergistic formulation of ⁇ , ⁇ -arteether for treatment of cerebral malaria.
  • Another objective of the present invention is to provide a formulation which is highly effective, easy to use, non-messy and non-cumbersome and can be administered by the rectal route to control cerebral malaria and which can also be used to clear a wide spectrum of infections resistant to most of the conventional antimalarials, antibiotic and other drug combinations.
  • Another objective of the invention is to provide a formulation effective in controlling malarial parasites in both asexual and sexual stages, in both drug sensitive and resistant malaria infections.
  • Yet another objective is to provide the rectal arteether can be effective in stopping malaria transmission and spread of the disease.
  • the present invention relates to a synergistic formulation comprising ⁇ / ⁇ arteether useful for the treatment of wide spectrum multi-drug resistant malaria and emergency treatment of comatose malaria
  • the formulation can be administered in malarial cases by rectal route in the form of rectal formulation, suppository in different doses form for infant, children, adults and pregnant woman
  • the above said formulation can be given by oral route also, for complete elimination of malaria infection.
  • the formulation would be effective in stopping the malarial transmission.
  • the invention also provides a process for the preparation of the said formulation
  • the invention provides a synergistic formulation comprising pharmaceutically effective amount of ⁇ / ⁇ arteether and a neutralized refined vegetable oil suitable for administration by rectal route
  • the vegetable oil is sterilized neutral refined oil that does not solidify in winter at room temperature
  • the ratio of ⁇ / ⁇ arteether and vegetable oil in the formulation is 0 002-0 020 1 w/w, preferably 0 0025 1 w/w
  • the vegetable oil is selected from the group comprising ground nut oil, sesame oil and tea oil.
  • ⁇ and ⁇ tautomers are present in a ratio of 10 90 to 30 70 In still another embodiment, the preferred ratio of ⁇ and ⁇ tautomers in the formulation is 30:70.
  • the formulation is used against a wide spectrum of Plasmodium yoelii nigeriensis (MDR II) parasite resistant to high oral doses of drugs selected from chloroquine, amodoquine, mepacrine, mefloquine, quinine, quinidine, pyrimethamine, pyronaridine, halofantrine, pyrimethamine+sulfadoxin, primaquine and WR 238605.
  • MDR II Plasmodium yoelii nigeriensis
  • the formulation is used against Plasmodium yoelii nigeriensis resistant to antibiotics selected from tetracycline, oxytetracycline, demeclocycline, erythromycin, ciprofloxacine, norfloxacine and doxycycline.
  • Plasmodium yoelii nigeriensis resistant to antimalarial-antibiotic combinational drugs selected from chloroquine +tetracycline, amodiaquine+tetracycline, mefloquine+tetracycline, mepacrine+tetracycline, quinine+tetracycline, quinine+oxytetracycline, quinine+doxycycline, quinine+erythromycin, cyprofloxacine +chloroquine, norfloxacine+chloroquine and quinine+tetracycline.
  • the said formulation is viscous and light yellow in colour.
  • the ⁇ and ⁇ tautomers in the formulation are present in a ratio of 10:90 to 30:70. and maintains longer half life (22 hrs or more).
  • the same formulation can also be made into regular rectal suppository which can be administered into rectum 3-4 times daily during acute phase of malaria.
  • the formulation can be used as substitute of primaquine and WR236805 and useful for interrupting transmission of P. falciparum because of its gametocytocidal action.
  • the formulation has a half life of about 22 hrs or more.
  • the formulation provides extended bioavailability because of longer T 1/2 ⁇ (clearance) in comparison to other artemisinin derivatives such as artemether or artesunate which have short plasma half life.
  • the formulation shows no adverse gastric effects, hemorrhage etc. which are found in the rectal or oral treatment with other artemisinin derivatives in tablet form.
  • the formulation is safe (LDso > 1250 mg/kg), well tolerated and much safer than artemether and artesunate in animal toxicity tests.
  • the formulation can be administered by rectal or oral routes or as gelatin capsule, given three to four times daily, and the formulation has shelf life of more than three years.
  • the formulation has 100-300 times more accumulation in the malarial infected red blood cells than the normal red blood cells.
  • the said formulation has adequate rectal absorption of compound sufficient to arrest the rising parasitaemia and the treated animals show significant reduction/clearance of parasitaemia indicating sufficient rectal drug absorption.
  • the formulation has blood schizontocidal activity as useful for the emergency treatment of uncomplicated severe complicated/cerebral and multi-drug resistant malarial infections including comatose malaria cases (for which it is the first line of emergency treatment).
  • the said formulation has no adverse met-hemoglobin type of toxicity which is known to be associated with administration of primaquine and WR236805.
  • the invention provides methods for the treatment of comatose cerebral malarial conditions comprising the steps of rectal administration of the formulation to a subject in need thereof.
  • the formulation is effective against sexual stage of parasites selected from P. falciparum, P. vivax and P. cynomolgi.
  • the formulation for rectal/oral treatment is used in the form of rectal formulation rectal suppositories/ oral gelatin capsules of liquid formulations in different dose forms for infants, children and adults.
  • the formulation is effective and safe in pregnant malaria infected monkeys, and could be useful for treatment of severe malaria in pregnant women.
  • the formulation is administered by the rectal route in children as well as adults for longer periods of once or twice a week until transmission continues
  • the process for the preparation of a formulation useful for the control of wide spectrum of malaria comprising (a) preparation of arteether ⁇ and ⁇ from artemisinin by known methods, (b) dissolving ⁇ / ⁇ arteether in sterilized neutral refined vegetable oil heating at 70-90°C for 2-4 min. and (c) cooling the solution at room temperature to obtain the desired formulation and (d) followed by sterilization of formulation by filtration through 0.45 ⁇ m filter.
  • the major advantage of the arteether rectal formulation will be to treat very serious cases/ comatose cases of cerebral malaria with a view to reduce mortality among P. falciparum cases particularly in children, pregnant women who are at maximum risk and can prove fatal unless the emergency therapy is instituted.
  • a still another advantage of the rectal formulation of arteether will be to control multi-drug resistant infections due primarily to P. falciparum which because of problem of resistance can not be treated effectively or cured with conventional antimalarial drugs such as chloroquine, mefloquine, amodiaquine, mepacrine, quinine, quinidine, halofantrin, pyrimethhamine, pyronaridine, WR238605 to which the parasite might be resistant, or with standard suppressive antimalarial antibiotics such as tetracycline, oxytetracycline, demeclocycline, doxycycline, erythromycin, ciprofloxacin, norfloxacin to which plasmodia may be resistant or with diverse antimalarial+antibiotic combination such as chloroquine, amodiquine/ mefloquine/ mepacrine/ quinine/ quinidine+tetracycline combinations or quinine/ quinidine+oxytetracycline combination, or qui
  • Another advantage of formulation will be to control chloroquine resistant P. vivax blood infections which are presently spreading in many continents could be effectively treated initially with rectal arteether formulation to prevent deterioration of the condition of the patient, and as soon as the patient is brought to the hospital arteether formulation can also be given parenterally as intramuscular (3 doses) curative treatment. All cases of P. falciparum and P. vivax which need a life saving therapy/those in coma /serious complicated P.
  • infants can be administered rectal arteether formulations 2-4 times daily to revive the comatose cases and rectal therapy used as emergency treatment can be changed to parenteral (oral) therapy with same arteether formulation (prepared in neutralized oil) which allows rapid drug absorption from gut and can provide effective control of parasitaemia, by oral route.
  • Rectal suppositories are simple to administer, easy to store at room temperature and administered, as it does not require any special equipment and can be given as emergency drug at rural health centers throughout the developing world. Suppository could be used in remote areas/villages incases who might not survive the long journey or delay in reporting to the hospital.
  • the formulation ( ⁇ / ⁇ -arteether and vehicle) is relatively safe as compared to other artemisinin derivatives (LDj 0 in mice>1250 mg/kg) and consequently the therapeutic index is more favorable for treatment of malaria.
  • the neutralized refined oil thus prepared was superior to commercial refined oil because it was stable even during winter on the shelf and did not solidify during overnight very low temperature. Accordingly, the present invention provides a process of the preparation of formulation useful for treatment of malaria, which comprises mixing 5 to 15% by weight of arteether with 85 to 95% by weight of neutralized refined ground nut oil which can be put into soft gelatin capsule for rectal treatment, or taking material in syringe and giving rectal administration of drug through a nozzle or catheter or prepare into standard suppository by known methods.
  • ⁇ / ⁇ arteether used may be selected from the mixture in different proportions ranging from 10-30 of ⁇ - and 70-90 of ⁇ -isomers.
  • the formulation used may be mixed with known suppository formulations such as glycerols substituted glycol, alkyl alcohol and mixture thereof.
  • the resulting composition (formulation and standard suppository materials) may be molded into desired shape and size.
  • the composition can also be made into a suppository like glycrine suppository or can be put in a soft gelatin capsule or the final formulations can be administered deep into rectum through plastic nozzle or rubber catheter 2-4 times daily for several days to reduce the parasitaemia to eliminate infection.
  • Neutralized oil Refined ground nut oil was purchased from commercial source locally. 100 ml oil was taken in separating funnel and to this 50 ml of sterile 5% sodium bicarbonate solution was added and was shaken for 10 min thoroughly to mix sodium bicarbonate with the oil. This solution was allowed to stand for 2 hrs, sodium bicarbonate layer was drawn out and fresh bicarbonate was added and process was repeated for 4 times to prepare neutralized oil. Last bicarbonate washing was continued for over night and after bicarbonate treatment, washing with sterilized deionized distilled water was started and likewise 4 washing of the treated oil were given with 50 ml distilled water. After the last washing, oil was filtered through double layered Whattman filter no.
  • Multi-drug resistant character of Plasmodium yoelii nigeriensis (MDR strain):
  • mice weighing 20 ⁇ 1 to 25 ⁇ 1 g of either sex and random laboratory bred at Central Drug Research Institute, Lucknow were used. Mice were routinely infected with lxlO 3 parasitized RBC intraperitoneally using sterile citrate saline as diluent for infected blood
  • the parasite suspension were inoculated in healthy mice by intraperitoneal route on day 0, and drugs were administered orally once a day for 4 doses (day 0 to day+ 3). From day 4 onwards, tail blood smears were examined after Giemsa staining and percent parasitaemia and mortality was recorded.
  • the parasite (MDR strain) was lethal for Swiss mice and mice died in 6-8 days after developing parasitaemia above 40% to 100% infection of RBC. Mortality was 100% in mice.
  • Table Present status of resistance pattern of P. yoelii nigeriensis (MDRII) strain to different antimalanals in Swiss mice.
  • ⁇ , ⁇ -Arteether mixture dissolved in neutralized ground-nut oil was administered to P. yoelh nigeriensis (MDR II) infected mice at 10 mg/kg to 20 mg/kg dose from day 0 to day 2 (for 3 consecutive days) by intra-rectal route
  • Drug was administered with 0 05-0 25 ml oil (vehicle) in single dose or in 2 divided dose daily
  • Parasitaemia was recorded daily from tail blood smears stained with Giemsa stain and results are given as % parasitaemia (means ⁇ SD) All the doses of arteether namely 10 0, 15 0 and 20 0 mg/kg suppressed the parasitaemia even after treatment (upto 5 days) as shown by blood smear examination The study shows that till day 5, the control mice had developed very high level of parasitaemia (57 6 ⁇ 24 7) and had starting dying whereas the groups of mice administered 15-20 mg/kg ⁇ , ⁇ -arteether formulation by rectal route treatment were fully protected as shown
  • Rectal formulation can easily control highly multi drug resistant malaria infections which do not respond to drugs like chloroquine, amodiaquine, mepacrine, mefloquine, halofantrine, quinine, quinidine, pyrimethamine +sulfadoxin etc. in MDR areas. Rectal route ⁇ / ⁇ arteether formulation remains 1 st line of emergency treatment of comatose P. falciparum cases in areas of MDR.
  • Swiss mice 25 ⁇ 1 gm infected intraperitoneally with 1x10 parasitized rbcs were administered ⁇ / ⁇ formulation, prepared in DMSO (3-4 drop) and then suspended in distilled water by oral administration at various doses ranging between 40-100 mg/kg for 5 consecutive days
  • Curative dose 60 mg/kg x 5 doses
  • yoelii nigeriensis MDR II was achieved As discussed above the bioavailability of oral arteether ⁇ / ⁇ (powder) prepared into dosage form in DMSO and distilled water is of lower order and a dose of 60 mg/kg x 5 days is needed for multi-drug resistant P. yoelii nigeriensis (MDRII) total clearance, whereas oral arteether ( ⁇ / ⁇ ) formulation in neutralized refined ground nut oil is much more effective and 50% drug dose (30 mg/kg x 5) is effective in 100% parasite clearance. Thus formulation in oil is superior for treatment of malaria.
  • P. falciparum clinical cases which were ganetocyte carriers were administered arteether formulation parenterally (intramuscular) at 150 mg dose (in neutralized ground nut oil) x 3 days for treatment of malaria, and within 48 h both asexual parasitaemia and gametocytes were completely cleared from the blood stream.
  • 8 cases 7 cases were cleared of gametocytes within 24 h of treatment while in the 8 th case gametocytes were cleared by 48 h.
  • the study shows strong gametocytocidal action of arteether formulation. All cases remained parasite free upto 28 days observation and drug cure rate was 100 percent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a synergistic formulation comprising pharmaceutically effective amount of alpha / beta arteether and a neutralized refined vegetable oil suitable for administration by rectal route, method for the treatment of cerebral and comatose malaria and process for the preparation of the said formulation.

Description

A SYNERGISTΪC ANTI-MALARIAL FORMULATION
Field of invention:
The present invention relates to novel synergistic formulation comprising α,β-arteether together with vegetable oil, said formulation useful in the treatment of comatose and cerebral malarial cases. The formulation specifically useful for rectal route treatment of highly multi-drug resistant P. falciparum and P. vivax cases and which can be used for emergency treatment of comatose and cerebral malaria. The invention also provides methods of treatment of malaria affecting the brain employing the novel formulation. The invention also provides process for preparation of the said novel formulation.
Background of invention :
According to WHO P. falciparum malaria is becoming increasing resistant to chloroquine, sulfadoxine-pyrimethamine and mefloquine (Eyles et al. 1963, Am. J. Torp. Med. Hyg. 12, 840-835; WHO Tech. Report Series No. 711, 1984; Boudreau et al. 1982 Lancet π, 1335; Nosten et al. 1991, Lancet 337, 1140-1143; Hurwitz et al. 1981, Lancet I, 1068-1070; Timmermanns etα/. 1982, Lancet I, 1181).
Although quinine resistance is also emerging along Thailand-Myanmar border, still the quinine and tetracycline combinations remains over 80% effective in practice (Vanijanonta et al. 1992, Lancet 339,369). Besides, seven day regimen of quinine and tetracycline was found to be effective in treating P.falciparum cases which were resistant to artesunate, artemether and mefloquine combined therapy.
Mefloquine was reported to produce neuropsychiatric side-effects in adults who developed tonic clonic fits. Besides psychosis, delusions and hallucinations, anxiety sleep disturbances were also reported after mefloquine (Drugs 1990, 39, 160-169).
Multi-drug-resistance in P. falciparum malaria and high level of P. vivax resistant strains are posing a major threat to countries in South-east Asia. Africa and Southern America. Most seriously affected areas include Thai-Myanmar Burmese border, where resistance to nearly all available drugs (Chlorquine, sulfadoxine-pyrimethamine, mefloquine, quinine) has already got established, (WHO Report on Infectious Diseases, 1999, WHO/CDS/99 1)
Halofantπne ts more effective but rather high doses of the drug are now required to control resistant P. falciparum (Brasseur et al 1993 Lancet 341, 901-2) which cold lead to increased risk of cardiotoxicity of this new antimalarial including sinus bradycardia, sinus arrhythmia, tall peak T waves, QT interval prolongation, ectopic beats (Karbwang et al 1993, Lancet, 342, 501, Wildling et al 1993 Lancet, 342, 55, Kremsner et al Am J Trop Med Hyg 50, 790-795) which has imposed great limitation on the antimalarial potential of this drug Several reports have recently appeared which document emergence of chloroquine resistance by P. vivax (Schwartz et al 1991 New England J Med 324, 927, Schuurkamp et al 1992 Trans R Soc Trop Med Hyg 86, 121-2, Murphy et al , 1993 Lancet, 341, 96-100, Garg et al 1995 Trans R Soc Trop Med Hyg 89, 656-7, Than et / 1995 Trans R Soc Trop Med Hyg 89, 307-8, Baird et al , 1996 Trans R Soc Trop Med Hyg 90, 409-410, Baird et al , Am J Trop Med Hyg 56, 627-63 1 The World Health Organization (1984) had accorded high priority to the development of fast acting artemisinin derivatives as blood schizontocides for the emergency treatment of cerebral malaria as well as for the control of multiple drug resistant cases of Plasmodium falciparum
α,β-arteether is an ethylether derivative of qinghaosu (artemisinine), which is extracted from Artemisia anniia, a plant long known in traditional Chinese medicine for its antimalarial properties α,β-Arteether (30 70) (intramuscular) is one of the artemisinin derivatives that has been developed in India and shows antimalarial activity against chloroquine, mefloquine and quinine resistant P. yoeln mgenensis and cures experimental cerebral malaria infections P. knowlesilP. fragile in rhesus monkey model) (Dutta et al 1989 Pharmacol Res 21, 415-19, Dutta and Tripathi, 1996, Japn J Trop Med Hyg 24. 65-69, Tripathi et al 1997, Exp Parasitol 87, 290-292, Bajpai et al 1989 Trans R Soc Trop Med Hyg 83, 484)
α/β-Arteether is relatively safer and its LD50 dose is 1250 mg/kg in Swiss mice as compared to artemether (LD50 263 mg/kg (im) and artesunate (LD50 475 mg/kg, im)(J Trad Chinese Med 1982,2(1) 31-38). Clinical trials of intramuscular injection of this compound have been completed and marketed Data on clinical trials with injectible preparation of α,β arteether (30 70 mixtures of isomers amongst P. falciparum cases has been published (Mohapatra et al 1996 Indian J Med Res 104, 284-7, Nalecha et al 1997, Int J Clin Pharm Res XNII (1) 11-15 Mohanty et al 1997 Trans. R Soc Trop Med Hyg 91, 328-330, Mishra et / 1995, Trans R Soc. Trop Med Hyg 89, 299-301)
Status of rectal suppositories of artemisinin derivatives
Several reports have been published which support the observation that rectal suppository preparations of artemisinin can exert antimalarial effect in reducing the P. falciparum parasitaemia in critically sick and and severe cases including cerebral complications (Li et al, Trans R Soc Trop Med Hyg 88(Suppl 1), 1994, 5-6, Arnold et al., Trans. R Soc Trop Med Hyg. 84, 1990, 499-502, Hien et al., Trans R.Soc. Trop Med Hyg. 85, 1991, 202- 211, Hien et al., Trans R Soc Trop Med. Hyg. 86, 1992, 582-583, Lie et al., J Trad Chinese Med 5, 1985, 159-161, Cao et al., 1997, Trans.R. Soc. Trop Med Hyg 91, 335- 342) The suppository treatment was found satisfactory for parasite clearance and for fever clearance in patients However, a very high dose of artemisinin (2800 mg in 48-56 h) is needed to be administered to produce complete parasite clearance Besides the high dose of artemisinin administered may approach the toxicity level and there are frequent problems of recrudescence with this drug in children.
Artesunate suppositories have also been used for control of severe P. falciparum cases Although they produce fast parasite clearance and fever clearance, the recrudescence rate is high Artesunate suppositories were given at a total dose of 1600 mg (in 8 doses) over 3 day course and in order to prevent recrudescence a long-acting antimalarial mefloquine ( 1250 mg) was administered to reduce recrudescence rate (92%) [Looareesuwan et al., Ann Trop Med Parasitol 89, 1995, 469-475, Looareesuwan et al., Jpn J Trop Med Hyg 24(suppl 1) 1996, 13-15] Looareesuwan also administered 1600 mg artesunate suppository which was followed by mefloquine (1250 mg) which produced 96% cure rate and Bhatt et al., [Jpn J Trop Med Hyg 24(suppl 1), 1996, 59-63] also used 1600 mg artesunate suppositories followed by 1000 mg mefloquine In spite of double treatment 13 6% mortality was recorded (cure rate 86 4%) Gomez [Gomez Landires, Jpn J Trop Med Hyg 24 (suppl 1) 1996, 16-24] employed 1400 mg artesunate suppository which was followed by 750 mg mefloquine They [Thwe et al., Jpn J Trop Med Hyg 24 (suppl 1) 1996, 25-32] administered 1200 mg artesunate suppositories (in 3 days) followed by 1250 mg , mefloquine for treatment of severe malaria and achieved a cure rate of 92 3% Halpaap et al, (1998, Am J Trop. Med. Hyg. 58, 365-368) administered two 50 mg artesunate suppositories at 4 h interval in children followed by sulfadoxin/pyrimethamine, and Sabchareon et al, (1998) administered 200 mg artesunate suppository (x 3 days) followed by mefloquine (2 doses)
Most of the trials recommend the administration of a second antimalarial like mefloquine or sulfadoxin/pyrimethamine with artesunate suppository Wilairatana et al, (1997, Ann J Trop Med Parasitol 91, 891-896) also reported that artesunate suppository was useful in reducing and clearing parasitaemia in severe P. falciparum cases Kyaw et al, (1996 Jpn J Trop Med Hyg 24 suppl. 1, 55-58) compared the efficacy of artesunate suppositories (200 mg x 3 days) and artemether suppositories (200 mg x 3 days) and the cure rates among adult uncomplicated falciparum cases were 50 and 43 9% respectively
Reference is to made to US Patent Application No 09/264,352 filed on February 12, 1999 in respect of formulation of dihydroartemisinin, effective in the control of a wide spectrum of malaria, wherein the Applicants had disclosed formulation comprising an artemisinin derivative This compound is a lactol derivative of artemisinin obtained from the plant artemisia annua. In the said application, the Applicants had formulated DHN capable of being administered by intramuscular, oral and rectal routes. DHA is an intermediate compound which is finally converted into its derivatives α,β-arteethers. The applicants during their study have now found that these compounds can be used for the treatment of malaria.
Objectives:
The main objective of the present invention is to provide a useful synergistic formulation of α,β-arteether for treatment of cerebral malaria.
Another objective of the present invention is to provide a formulation which is highly effective, easy to use, non-messy and non-cumbersome and can be administered by the rectal route to control cerebral malaria and which can also be used to clear a wide spectrum of infections resistant to most of the conventional antimalarials, antibiotic and other drug combinations.
Another objective of the invention is to provide a formulation effective in controlling malarial parasites in both asexual and sexual stages, in both drug sensitive and resistant malaria infections.
Yet another objective is to provide the rectal arteether can be effective in stopping malaria transmission and spread of the disease.
Another objective of the present invention is to give the rectal formulation of arteether in suppositories, as presumptive emergency treatment for comatose malaria cases (both P. falciparum and P. vivax) to arrest the rising parasitaemia and control infection in blood, which will revive the comatose cases to full conscious. Still another objective of the present invention is to provide a process for preparation of rectal formulation useful for treatment of malaria.
Summary of invention: The present invention relates to a synergistic formulation comprising α/β arteether useful for the treatment of wide spectrum multi-drug resistant malaria and emergency treatment of comatose malaria The formulation can be administered in malarial cases by rectal route in the form of rectal formulation, suppository in different doses form for infant, children, adults and pregnant woman The above said formulation can be given by oral route also, for complete elimination of malaria infection. The formulation would be effective in stopping the malarial transmission. The invention also provides a process for the preparation of the said formulation
Detailed description of the invention The invention provides a synergistic formulation comprising pharmaceutically effective amount of α/β arteether and a neutralized refined vegetable oil suitable for administration by rectal route
In an embodiment, the vegetable oil is sterilized neutral refined oil that does not solidify in winter at room temperature
In yet another embodiment of the present invention, the ratio of α/β arteether and vegetable oil in the formulation is 0 002-0 020 1 w/w, preferably 0 0025 1 w/w
In still another embodiment, the vegetable oil is selected from the group comprising ground nut oil, sesame oil and tea oil.
In yet another embodiment, α and β tautomers are present in a ratio of 10 90 to 30 70 In still another embodiment, the preferred ratio of α and β tautomers in the formulation is 30:70.
In an embodiment, the formulation is used against a wide spectrum of Plasmodium yoelii nigeriensis (MDR II) parasite resistant to high oral doses of drugs selected from chloroquine, amodoquine, mepacrine, mefloquine, quinine, quinidine, pyrimethamine, pyronaridine, halofantrine, pyrimethamine+sulfadoxin, primaquine and WR 238605.
In still another embodiment, the formulation is used against Plasmodium yoelii nigeriensis resistant to antibiotics selected from tetracycline, oxytetracycline, demeclocycline, erythromycin, ciprofloxacine, norfloxacine and doxycycline.
In yet another embodiment, is used against Plasmodium yoelii nigeriensis resistant to antimalarial-antibiotic combinational drugs selected from chloroquine +tetracycline, amodiaquine+tetracycline, mefloquine+tetracycline, mepacrine+tetracycline, quinine+tetracycline, quinine+oxytetracycline, quinine+doxycycline, quinine+erythromycin, cyprofloxacine +chloroquine, norfloxacine+chloroquine and quinine+tetracycline.
The said formulation is viscous and light yellow in colour.
In still another embodiment, the α and β tautomers in the formulation are present in a ratio of 10:90 to 30:70. and maintains longer half life (22 hrs or more). The same formulation can also be made into regular rectal suppository which can be administered into rectum 3-4 times daily during acute phase of malaria.
In yet another embodiment, the formulation can be used as substitute of primaquine and WR236805 and useful for interrupting transmission of P. falciparum because of its gametocytocidal action. In still another embodiment, the formulation has a half life of about 22 hrs or more.
In yet another embodiment, the formulation provides extended bioavailability because of longer T 1/2 β (clearance) in comparison to other artemisinin derivatives such as artemether or artesunate which have short plasma half life.
In still another embodiment, the formulation shows no adverse gastric effects, hemorrhage etc. which are found in the rectal or oral treatment with other artemisinin derivatives in tablet form.
In yet another embodiment, the formulation is safe (LDso>1250 mg/kg), well tolerated and much safer than artemether and artesunate in animal toxicity tests.
In still another embodiment, the formulation can be administered by rectal or oral routes or as gelatin capsule, given three to four times daily, and the formulation has shelf life of more than three years.
In yet another embodiment, the formulation has 100-300 times more accumulation in the malarial infected red blood cells than the normal red blood cells.
In still another embodiment, the said formulation has adequate rectal absorption of compound sufficient to arrest the rising parasitaemia and the treated animals show significant reduction/clearance of parasitaemia indicating sufficient rectal drug absorption.
In yet another embodiment, the formulation has blood schizontocidal activity as useful for the emergency treatment of uncomplicated severe complicated/cerebral and multi-drug resistant malarial infections including comatose malaria cases (for which it is the first line of emergency treatment). The said formulation has no adverse met-hemoglobin type of toxicity which is known to be associated with administration of primaquine and WR236805.
In one more embodiment, the invention provides methods for the treatment of comatose cerebral malarial conditions comprising the steps of rectal administration of the formulation to a subject in need thereof.
In still another embodiment, which can be administered through intra-recta or oral route or primarily by intra rectal followed by oral route.
In yet another embodiment, wherein the formulation is effective against sexual stage of parasites selected from P. falciparum, P. vivax and P. cynomolgi.
In still another embodiment, wherein the formulation is effective at much lower dose as gametocytocide compared to dose required for treatment of asexual blood stages.
In yet another embodiment, the formulation for rectal/oral treatment is used in the form of rectal formulation rectal suppositories/ oral gelatin capsules of liquid formulations in different dose forms for infants, children and adults.
In still another embodiment, the formulation is effective and safe in pregnant malaria infected monkeys, and could be useful for treatment of severe malaria in pregnant women.
In yet another embodiment, the formulation is administered by the rectal route in children as well as adults for longer periods of once or twice a week until transmission continues
In one more embodiment, the process for the preparation of a formulation useful for the control of wide spectrum of malaria comprising (a) preparation of arteether α and β from artemisinin by known methods, (b) dissolving α/β arteether in sterilized neutral refined vegetable oil heating at 70-90°C for 2-4 min. and (c) cooling the solution at room temperature to obtain the desired formulation and (d) followed by sterilization of formulation by filtration through 0.45 μm filter.
Novelty of the invention:
The major advantage of the arteether rectal formulation will be to treat very serious cases/ comatose cases of cerebral malaria with a view to reduce mortality among P. falciparum cases particularly in children, pregnant women who are at maximum risk and can prove fatal unless the emergency therapy is instituted.
A still another advantage of the rectal formulation of arteether will be to control multi-drug resistant infections due primarily to P. falciparum which because of problem of resistance can not be treated effectively or cured with conventional antimalarial drugs such as chloroquine, mefloquine, amodiaquine, mepacrine, quinine, quinidine, halofantrin, pyrimethhamine, pyronaridine, WR238605 to which the parasite might be resistant, or with standard suppressive antimalarial antibiotics such as tetracycline, oxytetracycline, demeclocycline, doxycycline, erythromycin, ciprofloxacin, norfloxacin to which plasmodia may be resistant or with diverse antimalarial+antibiotic combination such as chloroquine, amodiquine/ mefloquine/ mepacrine/ quinine/ quinidine+tetracycline combinations or quinine/ quinidine+oxytetracycline combination, or quinine+ erythromycin or ciprofloxacin+chloroquine combination, or norfloxacin+chloroquine combination against which the P. falciparum infection is resistant.
Another advantage of formulation will be to control chloroquine resistant P. vivax blood infections which are presently spreading in many continents could be effectively treated initially with rectal arteether formulation to prevent deterioration of the condition of the patient, and as soon as the patient is brought to the hospital arteether formulation can also be given parenterally as intramuscular (3 doses) curative treatment. All cases of P. falciparum and P. vivax which need a life saving therapy/those in coma /serious complicated P. falciparum infections/ life threatening malaria including children, infants can be administered rectal arteether formulations 2-4 times daily to revive the comatose cases and rectal therapy used as emergency treatment can be changed to parenteral (oral) therapy with same arteether formulation (prepared in neutralized oil) which allows rapid drug absorption from gut and can provide effective control of parasitaemia, by oral route.
The advantages of these formulations as prepared by the process of the present invention are that they provide a highly effective, easy to use, non messy and non cumbersome rectal delivery system to control cerebral malaria and which can also be used to clear highly multi-resistant malaria infections.
Rectal suppositories are simple to administer, easy to store at room temperature and administered, as it does not require any special equipment and can be given as emergency drug at rural health centers throughout the developing world. Suppository could be used in remote areas/villages incases who might not survive the long journey or delay in reporting to the hospital.
The formulation (α/β -arteether and vehicle) is relatively safe as compared to other artemisinin derivatives (LDj0 in mice>1250 mg/kg) and consequently the therapeutic index is more favorable for treatment of malaria.
The neutralized refined oil thus prepared was superior to commercial refined oil because it was stable even during winter on the shelf and did not solidify during overnight very low temperature. Accordingly, the present invention provides a process of the preparation of formulation useful for treatment of malaria, which comprises mixing 5 to 15% by weight of arteether with 85 to 95% by weight of neutralized refined ground nut oil which can be put into soft gelatin capsule for rectal treatment, or taking material in syringe and giving rectal administration of drug through a nozzle or catheter or prepare into standard suppository by known methods.
In an embodiment of the present invention, α/β arteether used may be selected from the mixture in different proportions ranging from 10-30 of α- and 70-90 of β-isomers.
In yet another embodiment of the present invention the formulation used may be mixed with known suppository formulations such as glycerols substituted glycol, alkyl alcohol and mixture thereof. The resulting composition (formulation and standard suppository materials) may be molded into desired shape and size. The composition can also be made into a suppository like glycrine suppository or can be put in a soft gelatin capsule or the final formulations can be administered deep into rectum through plastic nozzle or rubber catheter 2-4 times daily for several days to reduce the parasitaemia to eliminate infection.
The following example broadly illustrate the nature of this invention the manner in which it is to be performed without limiting the nature and scope of the invention.
Arteether formulation:
Preparation of neutralized oil for the formulation:
(a) Neutralized oil: Refined ground nut oil was purchased from commercial source locally. 100 ml oil was taken in separating funnel and to this 50 ml of sterile 5% sodium bicarbonate solution was added and was shaken for 10 min thoroughly to mix sodium bicarbonate with the oil. This solution was allowed to stand for 2 hrs, sodium bicarbonate layer was drawn out and fresh bicarbonate was added and process was repeated for 4 times to prepare neutralized oil. Last bicarbonate washing was continued for over night and after bicarbonate treatment, washing with sterilized deionized distilled water was started and likewise 4 washing of the treated oil were given with 50 ml distilled water. After the last washing, oil was filtered through double layered Whattman filter no. 3, the filtration process was continued over night and neutralized oil was collected. The neutralized oil thus obtained was passed through 2nd set of Whattman filter paper to obtain moisture free clear neutralized oil. The washed neutralized oil was put in sterilized flask and it was heated on hot plate to 140°C for 1 hr. The oil was aseptically dispensed in glass stopped bottle to avoid aeration/oxidation. This oil could be stored at room temperature on the shelf as light yellowish coloured liquid. This neutralized oil is used for preparation of rectal formulation.
(b) Preparation of rectal arteether formulation: Stock solution of the drug α/β arteether (30:70) mixture of enantiomers α and β respectively, was prepared in neutralized refined ground nut oil. Arteether α and β were finally dissolved in neutralized ground nut oil to get the desired drug solution for administration. The mixture was heated to 70-90°C to dissolve the arteether and the final drug solution was filtered through 0.45 μ millipore filter. The arteether preparation is of light yellowish colour and is stable for over 3 years. For animal experiments various dose level of drug arteether can be made by dilution of the drug stock with neutralized oil vehicle. The arteether formulation can be used for preparing rectal formulation and can also be administered orally to achieve curative action.
(c) Method for the preparation of suppository: A mixture of polyethylene glycol (PEG Mol. Wt. 1500), 350 mg, polyethylene glycol (Mol. Wt. 4000) 150 mg and hexane- l-ol (0.1 ml) was melted by heating on a water bath and 150 mg of α/β-arteether in two ml of hexane was added to it with intimate mixing. The hexane was evaporated off by warming the mixture to 60°C and the mixture was allowed to cool to get solid mass which was molded into suppositories of oval shape and 1 x 1 x 0.5 cm size. It was then packed in a polyethylene lined blister type packing to avoid coming into contact with moisture before use. Besides other known suppository materials can be used to prepare the formulation. Biological activity:
Examples: ! Multi-drug resistant character of Plasmodium yoelii nigeriensis (MDR strain):
Swiss mice weighing 20±1 to 25±1 g of either sex and random laboratory bred at Central Drug Research Institute, Lucknow were used. Mice were routinely infected with lxlO3 parasitized RBC intraperitoneally using sterile citrate saline as diluent for infected blood The parasite suspension were inoculated in healthy mice by intraperitoneal route on day 0, and drugs were administered orally once a day for 4 doses (day 0 to day+ 3). From day 4 onwards, tail blood smears were examined after Giemsa staining and percent parasitaemia and mortality was recorded. The parasite (MDR strain) was lethal for Swiss mice and mice died in 6-8 days after developing parasitaemia above 40% to 100% infection of RBC. Mortality was 100% in mice.
Table: Present status of resistance pattern of P. yoelii nigeriensis (MDRII) strain to different antimalanals in Swiss mice.
Example 2
Rectal formulation of α/β arteether:
α,β-Arteether mixture dissolved in neutralized ground-nut oil was administered to P. yoelh nigeriensis (MDR II) infected mice at 10 mg/kg to 20 mg/kg dose from day 0 to day 2 (for 3 consecutive days) by intra-rectal route Drug was administered with 0 05-0 25 ml oil (vehicle) in single dose or in 2 divided dose daily Parasitaemia was recorded daily from tail blood smears stained with Giemsa stain and results are given as % parasitaemia (means±SD) All the doses of arteether namely 10 0, 15 0 and 20 0 mg/kg suppressed the parasitaemia even after treatment (upto 5 days) as shown by blood smear examination The study shows that till day 5, the control mice had developed very high level of parasitaemia (57 6±24 7) and had starting dying whereas the groups of mice administered 15-20 mg/kg α,β-arteether formulation by rectal route treatment were fully protected as shown by negative parasitaemia. The study shows fairly rapid drug absorption of this formulation by rectal route which was effective in initially controlling multi-drug resistant (II) P. yoelii nigeriensis infection in mice. Presumptive arteether rectal formulation or suppository administration can save mortality in severe/complicated cases, α/β Arteether rectal route controls the severity of infection and prevents mortality in severe complicated comatose malaria cases and will be specially useful in infants, children and those having frequent vomiting and can not be given oral formulation initially. Rectal formulation can easily control highly multi drug resistant malaria infections which do not respond to drugs like chloroquine, amodiaquine, mepacrine, mefloquine, halofantrine, quinine, quinidine, pyrimethamine +sulfadoxin etc. in MDR areas. Rectal route α/β arteether formulation remains 1st line of emergency treatment of comatose P. falciparum cases in areas of MDR.
Table Blood schizontocidal action of arteether α/β formulation on multi-resistant P yoelii nigeriensis (MDR II) infection in Swiss mice (25±lg) by rectal route of administraUon
"The dose was given in 2 divided doses at 6 hrs intervals Number of animals given in parenthesis
Example 3
Oral use of formulation
3a). Blood schizonticidal activity of orally administered arteether formulationprepared in DMSO-distilled water against MDRII P. yoelii niseriensis infection in Swiss mice (25 + 1 g)
Swiss mice 25 ± 1 gm infected intraperitoneally with 1x10 parasitized rbcs were administered α/β formulation, prepared in DMSO (3-4 drop) and then suspended in distilled water by oral administration at various doses ranging between 40-100 mg/kg for 5 consecutive days
Parasitaemia was recorded periodically from tail blood smears upto 28 days of observation Both 60 and 80 mg/kg x 5 doses were able to eliminate the parasitaemia upto 28 days of observation and were curative The 40 mg/kg dose provided transient suppression of parasitaemia, but was not curative against MDR strain A very high dose is required for curative action against MDR infection and its bioavailability by oral route as suspension in D W is low
Curative dose = 60 mg/kg x 5 doses
3b). Oral administration of arteether formulation (in oil):
Efficacy of oral administration of arteether formulation for control of blood induced multi- drug resistant P. yoelii nigeriensis (MDR II) in Swiss mice (25+1 g) was evaluated The mice was infected intraperitoneally with lxl0D parasitized RBC, and drug treatment 10,15,20 and 30 mg/kg was given once daily for five consecutive days (starting from day 0 to day 4) Blood smears made from tail blood and stained with giemsa were examined periodically till 28 days of infection to record parasitaemia levels and number of surviving/cured mice till 28 days The results set in table show that the arteether formulation (in neutralized refined ground nut oil) was curative (8/8) in 5 day treatment schedule at 30 mg/kg dose schedule Both 15 and 20 mg/kg doses cleared the parasitaemia for 6-7 day but there was recrudescence later even though 4-5 mice out of 8 mice (treated in group) showed complete parasite clearance by day 28 Data show adequate drug absorption after oral use of the formulation in neutralized oil and ultimate control of highly multi drug resistant malaria infection (P. yoelii nigeriensis MDR II) was achieved As discussed above the bioavailability of oral arteether α/β (powder) prepared into dosage form in DMSO and distilled water is of lower order and a dose of 60 mg/kg x 5 days is needed for multi-drug resistant P. yoelii nigeriensis (MDRII) total clearance, whereas oral arteether (α/β) formulation in neutralized refined ground nut oil is much more effective and 50% drug dose (30 mg/kg x 5) is effective in 100% parasite clearance. Thus formulation in oil is superior for treatment of malaria.
Table Blood schizonucidal acϋvity of a/b arteether formulauon in neutralized oil by oral route against P voelu nigeriensis (MDR II) in Swiss mice.
Number of mice surviving are shown in parenthesis Example 4
4. Transmission blocking activity of α/β arteether formulation in clinical malaria case (P. falciparum):
P. falciparum clinical cases (no=8) which were ganetocyte carriers were administered arteether formulation parenterally (intramuscular) at 150 mg dose (in neutralized ground nut oil) x 3 days for treatment of malaria, and within 48 h both asexual parasitaemia and gametocytes were completely cleared from the blood stream. Out of 8 cases, 7 cases were cleared of gametocytes within 24 h of treatment while in the 8th case gametocytes were cleared by 48 h. The study shows strong gametocytocidal action of arteether formulation. All cases remained parasite free upto 28 days observation and drug cure rate was 100 percent. For control and total clearance of asexual parasites arteether 150 mg/kg x 3 days treatment is necessary but to achieve gametocyte clearance even one dose (150 mg/kg/60 kg adult) may be given once a week or maximum twice a week to knock out P. falciparum gametocytes.
Table Blood schizontocidal and gametocytocidal effect of α/β arteether formulation based on gametocyte and asexual parasite clearance rate in P. falciparum cases

Claims

CLAIMS1 A synergistic formulation comprising pharmaceutically effective amount of α/β arteether and a neutralized refined vegetable oil suitable for administration by rectal route2 A formulation as claimed in claim 1, wherein the vegetable oil is sterilized neutral refined oil that does not solidify in winter at room temperature3 A formulation as claimed in claim 1, wherein the ratio of α/β arteether and vegetable oil in the formulation is 0 002-0 020- 1 w/w, preferably 0 0025 1 w/w 4 A formulation as claimed in claim 1, wherein the vegetable oil is selected from the group comprising ground nut oil, sesame oil and tea oil5 A formulation as claimed in claim 1, wherein α and β tautomers are present in a ratio of 10 90 to 30 706 A formulation as claimed in claim 1, wherein the preferred ratio of α and β tautomers in the formulation is 30 707 A formulation as claimed in claim 1, wherein the formulation is used against a wide spectrum of Plasmodium yoeln nigeriensis (MDR II) parasite resistant to high oral doses of drugs selected from chloroquine, amodoquine, mepacrine, mefloquine, quinine, quinidine, pyrimethamine, pyronaridine, halofantrine, pyrimethamine+sulfadoxin, primaquine and WR 238605.8 A formulation as claimed in claim 1, wherein the formulation is used against Plasmodium yoeln nigeriensis resistant to antibiotics selected from tetracycline, oxytetracycline, demeclocycline, erythromycin, ciprofloxacine, norfloxacine and doxycycline 9 A formulation as claimed in claim 1, wherein is used against Plasmodium yoel nigeriensis resistant to antimalarial-antibiotic combinational drugs selected from chloroquine +tetracycline, amodiaquine+tetracycline, mefloquine+tetracycline, mepacrine+tetracycline, quinine+tetracycline, quinine+oxytetracycline, quinine+doxycycline, quinine+erythromycin, cyprofloxacine +chloroquine, norfloxacine+chloroquine and quinine+tetracycline 10 A α/β arteether formulation as claimed in any one of claims 1 to 8, wherein the said formulation is viscous and light yellow in colour 1 1 A formulation as claimed in claim 1, wherein α and β tautomers are present in a ratio of 10 90 to 30 70 and maintains longer half life (22 hrs or more) The same formulation can also be made into regular rectal suppository which can be administered into rectum 3-4 times daily during acute phase of malaria12 A formulation as claimed in claim I, that is used as substitute of primaquine and WR236805 and useful for interrupting transmission of P. falciparum because of its gametocytocidal action.13 A formulation as claimed in claim 1, that has a half life of about 22 hrs or more14 A formulation as claimed in claim 1, that provides extended bioavailability because of longer T 1/2 β (clearance) in comparison to other artemisinin derivatives such as artemether or artesunate which have short plasma half life.15 A formulation as claimed in claim 1, wherein the formulation shows no adverse gastric effects, hemorrhage etc which are found in the rectal or oral treatment with other artemisinin derivatives in tablet form.16 A formulation as claimed in claim 1, which is safe (LD50>1250 mg/kg), well tolerated and much safer than artemether and artesunate in animal toxicity tests 17 A formulation as claimed in claim 1, which is for rectal or oral use in gelatin capsule, given three to four times daily, wherein the formulation has shelf life of more than three years 18 A formulation as claimed in claim 1, wherein the formulation has 100-300 times more accumulation in the malarial infected red blood cells than the normal red blood cells 19 A formulation as claimed in claim 1, wherein the said formulation has adequate rectal absorption of compound sufficient to arrest the rising parasitaemia and the treated animals show significant reduction/clearance of parasitaemia indicating sufficient rectal drug absorption20 A formulation as claimed in claim 1, having blood schizontocidal activity as useful for the emergency treatment of uncomplicated severe complicated/cerebral and multi-drug resistant malarial infections including comatose malaria cases (for which it is the first line of emergency treatment)21 A formulation as claimed in claim 1, wherein the said formulation has no adverse met-hemoglobin type of toxicity which is known to be associated with administration of primaquine and WR236805 22 A method for the treatment of comatose cerebral malarial conditions comprising the steps of rectal administration of the formulation as claimed in claim 1 to a subject in need thereof 23 A method as claimed in claim 22, which can be administered through intra-recta or oral route or primarily by intra rectal followed by oral route 24 A method as claimed in claim 22, wherein the formulation is effective against sexual stage of parasites selected from P falciparum, P vivax and P cynomolgi 25 A method as claimed in claim 22, wherein the formulation is effective at much lower dose as gametocytocide compared to dose required for treatment of asexual blood stages 26 A method as claimed in claim 22, wherein the formulation for rectal oral treatment is used in the form of rectal formulation/ rectal suppositories/ oral gelatin capsules of liquid formulations in different dose forms for infants, children and adults27 A method as claimed in claim 22, wherein the formulation is effective and safe in pregnant malaria infected monkeys, and could be useful for treatment of severe malaria in pregnant women28 A method as claimed in claim 22, wherein the formulation is administered by the rectal route in children as well as adults for longer periods of once or twice a week until transmission continues A process for the preparation of a formulation useful for the control of wide spectrum of malaria comprising (a) preparation of arteether α and β from artemisinin by known methods, (b) dissolving α/β arteether in sterilized neutral refined vegetable oil heating at 70-90°C for 2-4 min and (c) cooling the solution at room temperature to obtain the desired formulation and (d) followed by sterilization of formulation by filtration through 0 45 μm filter A process for the preparation of a formulation as claimed in claim 1 useful for treatment of malaria, which comprises mixing 5 to 15% by weight of arteether with 85 to 95% by weight of neutralized refined ground nut oil which can be put into soft gelatin capsule for rectal treatment, or taking material in syringe and giving rectal administration of drug through a nozzle or catheter or prepare into standard suppository by known methods A process as claimed in claim 30 wherein the arteether is selected from α, β arteether in proportions ranging from 10-30 of α- and 70-90 of β-isomers A process as claimed in claim 30 wherein the formulation is mixed with known suppository formulations such as glycerols substituted glycol, alkyl alcohol and mixture thereof AMENDED CLAIMS[received by the International Bureau on 20 February 2001 (20.02.01); original claims 1 and 5 amended; remaining claims unchanged (1 page)]
1. A formulation comprising α,β-arteether in combination with sterilized, neutralized refined vegetable oil, for the treatment of multi-drug resistant malaria caused by malarial parasites, wherein the ratio of α,β-tautomers in the formulation is 10:90 to 30:70 and the formulation is administered by rectal route.
2. A formulation as claimed in claim 1, wherein the vegetable oil does not solidify in winter at room temperature.
3. A formulation as claimed in claim 1, wherein the ratio of α/β arteether and vegetable oil in the formulation is 0.002-0.020:1 w/w, preferably 0.0025:1 w/w.
4. A formulation as claimed in claim 1, wherein the vegetable oil is selected from the group comprising ground nut oil, sesame oil and tea oil.
5. A formulation as claimed in claim 1, wherein the preferred ratio of α and β tautomers in the formulation is 30:70.
6. A formulation as claimed in claim 1, wherein the formulation is used against a wide spectrum of Plasmodium yoelii nigeriensis (MDR II) parasite resistant to high oral doses of drugs selected from chloroquine, amodoquine, mepacrine, mefloquine, quinine, quinidine, pyrimethamine, pyronaridine, halofantrine, pyrimethamine+sulfadoxin, primaquine and WR 238605.
7. A formulation as claimed in claim 1, wherein the formulation is used against Plasmodium yoelii nigeriensis resistant to antibiotics selected from tetracycline, oxytetracycline, demeclocycline, erythromycin, ciprofloxacine, norfloxacine and doxycycline.
SUBSTITUTE SHEET ARTICLE 19
EP00940733A 2000-03-31 2000-03-31 A synergistic anti-malarial formulation Ceased EP1267864A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2000/000039 WO2001074353A1 (en) 2000-03-31 2000-03-31 A synergistic anti-malarial formulation

Publications (1)

Publication Number Publication Date
EP1267864A1 true EP1267864A1 (en) 2003-01-02

Family

ID=11076239

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00940733A Ceased EP1267864A1 (en) 2000-03-31 2000-03-31 A synergistic anti-malarial formulation

Country Status (3)

Country Link
EP (1) EP1267864A1 (en)
AU (1) AU2000255631A1 (en)
WO (1) WO2001074353A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023897A1 (en) * 2001-11-13 2004-02-05 Caplan Michael J. Methods for preventing or treating disease mediated by toxin-secreting bacteria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68906345T2 (en) * 1988-10-07 1993-10-28 Hoechst Ag Antimalarial compositions utilizing quinidine, artemisinin and their derivatives.
CN1058717A (en) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 New antimalarial agent-Coartem and preparation method thereof
CH692321A5 (en) * 1997-11-03 2002-05-15 Mepha Ag Pharmaceutically effective composition which comprises an effective anti-malarial parasite substance.
IN191696B (en) * 1999-02-12 2003-12-20 Council Scient Ind Res

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0174353A1 *

Also Published As

Publication number Publication date
WO2001074353A1 (en) 2001-10-11
AU2000255631A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
Qinghaosu Antimalaria studies on Qinghaosu
CN1085527C (en) Preparation method of synergistic antimalarial compound benzfluorenol
KR101512495B1 (en) Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction
Nosten et al. New antimalarials: a risk-benefit analysis
US6326023B1 (en) Synergistic anti-malarial formulation
Bunnag et al. Artemether in the treatment of multiple drug resistant falciparum malaria
Thillainayagam et al. Mosquito, malaria and medicines-A Review
CN1041694A (en) The anti-malaria composition of quinidine, arteannuin and derivant thereof and Therapeutic Method
JPH08504403A (en) Therapeutic compounds derived from Neem tree
DE69936186T2 (en) Dihydroartemisinin formulation for the treatment of various types of malaria
EP1835921B1 (en) 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
HU200688B (en) Process for producing pharmaceutical composition against malaria
AU2006238506A1 (en) Association between ferroquine and an artemisinine derivative for treating malaria
WO2001074353A1 (en) A synergistic anti-malarial formulation
ZA200208485B (en) A synergistic anti-malarial formulation.
DE69816520T2 (en) Treatment of infections caused by unicellular organisms
Puri et al. Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys
US4920147A (en) Deoxoartemisinin: new compound and composition for the treatment of malaria
US5023353A (en) Deoxoartemisinin: new compound and composition for the treatment of malaria
US20060141024A1 (en) Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria
JP2021116291A (en) Pharmaceutical composition containing 2,4-diamino-6,7-dimethoxy quinazoline derivative as an active ingredient, and 2,4-diamino-6,7-dimethoxy quinazoline derivative having specific structure
Bunnag et al. Intramuscular artemether in female patients with uncomplicated falciparum malaria
KR100903287B1 (en) Composition for the prevention and treatment of toxoplasmosis containing 7-ethoxycoumarin as an active ingredient
Maki et al. Larvicidal effect of flubendazole on Angiostrongylus cantonensis in mice with various worm burdens
CN101225087A (en) Coumarether compound and use of its composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20041026

17Q First examination report despatched

Effective date: 20041026

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100408